The Ceiling
Why More Isn't More: The Dose Ceiling Most Protocols Ignore
Some compounds don't work by acting on you. They work by asking your body to act on itself — and your body has a limit, a feedback loop, and an off switch.
There are two ways to raise a hormone level.
Supply it. Inject the hormone. What you put in is what you get, and if you put in more, you have more. Straightforward, and largely unbounded — you can push levels well past anything the body would produce on its own.
Ask for it. Give something that signals a gland to release its own supply.
An entire class of peptides works the second way. And the second way has a property the first doesn't: you're making a request, and the system receiving it is allowed to decline.
Three separate mechanisms let it decline. Understanding them changes how you read every protocol built on these compounds.
What a secretagogue is
A secretagogue is a substance that stimulates the body to release something. In the growth hormone system, it doesn't act at the receptor for the hormone you're interested in. It acts upstream, on the gland, telling it to release what it already has.
Two families do this. One mimics the natural releasing signal from the hypothalamus. The other mimics a separate hunger-related hormone that also triggers release. Both converge on the same pituitary cells; both amount to a request.
The distinction from direct hormone injection isn't a technicality. It's the difference between adding water to a tank and asking someone to open a valve. The second depends entirely on what's behind the valve — and on whether whoever's holding it agrees with you.
Limit one: the tank isn't infinite
Your pituitary stores growth hormone in packets, ready to release. A stimulus releases what's stored.
That store is finite. Once released, it has to be replaced — and replacement means synthesizing new hormone, which takes time.
So a stimulus applied to a full store produces a large release. The same stimulus applied twenty minutes later, to a partially depleted store, produces less. Not because the stimulus weakened, but because there's less behind the valve.
More signal doesn't create more hormone. It can only release what's there.
Limit two: the system actively pushes back
This is the mechanism people most often leave out.
Growth hormone doesn't circulate in isolation. It travels to the liver and prompts production of a second messenger, IGF-1 — insulin-like growth factor 1, named for its structural resemblance to insulin — which carries out much of the downstream effect. And IGF-1 does something else: it goes back and suppresses the whole system that produced it. It acts on the pituitary to reduce release, and prompts the hypothalamus to increase its own inhibitory signal.
The more you succeed at raising output, the harder the system works to bring it back down.
This is the sharpest difference between asking and supplying. Injected hormone bypasses feedback entirely — the loop can suppress your own production, but it can't remove what you injected. A secretagogue works through the loop, which means the loop gets a vote.
Limit three: the receptor stops listening
The third mechanism sits at the point of contact.
Receptors aren't passive. Stimulate one continuously and the cell responds by reducing its sensitivity — modifying the receptors, pulling them inside the cell, and eventually making fewer of them. It's a protective adaptation, and it's a general property of this receptor family, not a quirk of any particular compound.
There's documented variation between compounds in how quickly this sets in. Some of these peptides show a clearly diminishing response with continued administration; others hold up better. The variation is real and it's one of the few things worth knowing about a specific compound in this class.
The proof that timing is a signal
Everything above suggests that how often matters as much as how much. Here's the demonstration — and it isn't theoretical. It's the mechanism of an approved cancer drug.
In the reproductive system, the hypothalamus releases gonadotropin-releasing hormone (GnRH) in pulses. Those pulses drive the pituitary to release the hormones controlling testosterone and oestrogen production.
Now give the same signal continuously instead of in pulses.
The system doesn't respond more. It shuts down. Continuous stimulation of a receptor built for pulses causes the pituitary to withdraw and stop responding — and testosterone production collapses.
That's exactly how the -relin drugs from Article 2 work in prostate cancer. Same molecule. Same receptor. Pulsed, it stimulates. Continuous, it suppresses. Opposite outcomes from identical chemistry, determined by nothing but timing.
This reframes something from Article 1. The long-acting version of CJC-1295 stays in circulation for around a week — producing continuous stimulation of a system that runs on bursts. Whether that's an advantage or a fundamental design mismatch is a real pharmacological question. But it's the right question, and it's invisible unless you know pulsatility is a variable.
What this does to escalation logic
Put the three limits together and the shape of the dose-response curve follows.
Below the ceiling, more signal produces more hormone. Above it, the store is depleted, feedback is engaged, and receptors are desensitizing. Additional dose produces no additional release.
Off-target effects don't share that ceiling. They scale with concentration, straightforwardly. Depending on the compound, that can mean effects on appetite, on other pituitary hormones like cortisol and prolactin, on water retention, on injection sites.
So past the ceiling:
Benefit plateaus. Side effects don't.
Every increment above that point is pure cost. And escalation is exactly the logic most informal protocols are built on — if some produced an effect, more should produce more, and a plateau means you haven't pushed hard enough.
For this class of compound, a plateau doesn't mean push harder. It means you found the ceiling, which was always going to be there.
The honest case for the other side
There's a real argument in favour of this class, and it follows directly from everything above.
Because secretagogues work through the feedback loop, the loop constrains them. You can't drive levels to arbitrary heights the way you can by injecting the hormone directly, because the system fights back. Whatever else is true, that's a genuine structural difference in risk profile, and it's the strongest honest argument anyone makes for these compounds.
Three limits on it, though.
Buffered isn't protected. A ceiling on the primary effect says nothing about off-target effects, which have no such ceiling.
Regulation isn't infinite. Feedback loops can be pushed hard enough that the pushback becomes the problem — that's precisely how the continuous-stimulation shutdown above works.
And most of these compounds aren't approved. One growth hormone secretagogue is an approved drug with a defined indication and a real safety database — macimorelin, used diagnostically to test for adult growth hormone deficiency. The rest aren't, which means the feedback argument is being applied to compounds nobody has characterised properly in humans.
An argument about mechanism isn't a substitute for evidence about outcomes.
Next
We've now covered what these molecules are, how they're classified, why they're injected, how they're built, whether their pieces work, and how much is too much.
One thing left before we put it all together: what else is in your system when you take them. There's a claim about peptides and drug interactions that's half true — and the half that's false has consequences serious enough that surgical guidance had to be rewritten around it.
This article is educational and not medical advice. It does not recommend any compound, dose, or protocol. Most compounds discussed are not approved for human use. Decisions about any therapy belong with a qualified clinician who knows your history.